magnsium sulfate

Phase 3Small molecule

AAssiut University

magnsium sulfate is one of 3 small molecule programs targeting Laryngospasm. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LaryngospasmActive, not recruiting

LaryngospasmPhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Laryngospasm

#DrugCompanyPhaseTrials

magnsium sulfate

AAssiut University

Phase 3

1 2

Xylocaine

MMEDRx USA, Inc.

Preclinical

2 3

Levobupivacaine Hydrochloride

KKAT General Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Not yet recruiting

Laryngospasm

NCT06761547

Clinical

Trials by Indication[1]

Laryngospasm1 trial

Comparsion of Intravenous Injection of Magnesium Sulfate and Lidocaine Effectiveness on the Prevention of Laryngospasm and Analgesic Requirement in Tonsillectomy

Not yet recruiting·—·Phase 3·NCT06761547·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for magnsium sulfate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — magnsium sulfate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for magnsium sulfate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assiut University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssiut University

magnsium sulfate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Laryngospasm1 trial

References

Drug Info

Quick Facts

Related News